​

MBX Biosciences (MBX) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

MBX Stock Forecast

MBX Biosciences (MBX) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $80.50, with a high of $90.00 and a low of $56.00. This represents a 17.69% increase from the last price of $68.40.

MBX Stock Rating

MBX Biosciences stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 7 Strong Sell Sell Hold Buy Strong Buy

MBX Price Target Upside V Benchmarks

TypeNameUpside
StockMBX Biosciences17.69%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts3312
Avg Price Target$88.67$88.67$66.17
Last Closing Price$68.40$68.40$68.40
Upside/Downside29.63%29.63%-3.26%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Aug, 2629---11
Jul, 2629-1-12
Jun, 2629-1-12
May, 2629-1-12
Apr, 2629-1-12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 10, 2026Truist Financial$88.00$65.8733.60%28.65%
Aug 07, 2026Barclays$88.00$67.1131.13%28.65%
Jul 23, 2026Michael YeeUBS$90.00$61.8445.54%31.58%
May 12, 2026Stifel Nicolaus$56.00$38.9943.63%-18.13%
May 12, 2026Barclays$70.00$40.0874.65%2.34%
May 11, 2026Srikripa DevarakondaTruist Financial$70.00$43.7959.85%2.34%
Mar 09, 2026Srikripa DevarakondaTruist Financial$50.00$28.7873.73%-26.90%
Jan 27, 2026Barclays$66.00$36.0782.98%-3.51%
Jan 16, 2026Seamus FernandezGuggenheim$88.00$40.91115.11%28.65%
Jan 07, 2026Michael YeeUBS$60.00$28.70109.06%-12.28%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 07, 2026BarclaysOverweightOverweighthold
Jul 23, 2026UBSBuyBuyhold
May 12, 2026BarclaysOverweightOverweighthold
May 12, 2026CitigroupOutperformOutperformhold
Mar 12, 2026Cowen & Co.BuyBuyhold
Feb 24, 2026UBSBuyBuyhold
Jan 27, 2026BarclaysOverweightinitialise
Jan 16, 2026GuggenheimBuyBuyhold
Jan 07, 2026UBSBuyinitialise
Dec 04, 2025Goldman SachsSellinitialise

Financial Forecast

EPS Forecast

$-25 $-20 $-15 $-10 $-5 $0 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-1.85$-2.38----
Avg Forecast$-11.52$-2.82$-2.76$-3.45$-2.95$-2.77
High Forecast$-5.28$-2.44$-2.25$-3.22$-2.95$-2.77
Low Forecast$-23.87$-3.11$-3.08$-3.69$-2.95$-2.77
Surprise %-83.94%-15.60%----

Revenue Forecast

Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported------
Avg Forecast-----$44.05M
High Forecast-----$44.05M
Low Forecast-----$44.05M
Surprise %------

Net Income Forecast

$-800M $-650M $-500M $-350M $-200M $-50M Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-61.92M$-86.97M----
Avg Forecast$-486.68M$-102.04M$-89.01M$-115.46M$-98.51M$-92.50M
High Forecast$-176.21M$-81.59M$-75.30M$-107.56M$-98.51M$-92.50M
Low Forecast$-797.16M$-103.73M$-102.71M$-123.35M$-98.51M$-92.50M
Surprise %-87.28%-14.77%----

MBX Forecast FAQ

Is MBX Biosciences stock a buy?

MBX Biosciences stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that MBX Biosciences is a favorable investment for most analysts.

What is MBX Biosciences's price target?

MBX Biosciences's price target, set by 7 Wall Street analysts, averages $80.5 over the next 12 months. The price target range spans from $56 at the low end to $90 at the high end, suggesting a potential 17.69% change from the previous closing price of $68.4.

How does MBX Biosciences stock forecast compare to its benchmarks?

MBX Biosciences's stock forecast shows a 17.69% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for MBX Biosciences over the past three months?

  • August 2026: 18.18% Strong Buy, 81.82% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 16.67% Strong Buy, 75.00% Buy, 0% Hold, 8.33% Sell, 0% Strong Sell.
  • June 2026: 16.67% Strong Buy, 75.00% Buy, 0% Hold, 8.33% Sell, 0% Strong Sell.

What is MBX Biosciences’s EPS forecast?

MBX Biosciences's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.76, marking a 15.97% increase from the reported $-2.38 in 2025. Estimates for the following years are $-3.45 in 2027, $-2.95 in 2028, and $-2.77 in 2029.

What is MBX Biosciences’s revenue forecast?

MBX Biosciences's average annual revenue forecast for its fiscal year ending in December 2026 is $0, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $0, followed by $0 for 2028, and $44.05M for 2029.

What is MBX Biosciences’s net income forecast?

MBX Biosciences's net income forecast for the fiscal year ending in December 2026 stands at $-89.007M, representing an 2.34% increase from the reported $-86.971M in 2025. Projections indicate $-115M in 2027, $-98.508M in 2028, and $-92.498M in 2029.